Epinecidin-1 antimicrobial activity: In vitro membrane lysis and In vivo efficacy against Helicobacter pylori infection in a mouse model

Biomaterials

Volumn 61, Issue , 2015, Pages 41-51

  Narayana, Jayaram Lakshmaiah ^a,b   Huang, Han Ning ^b   Wu, Chang Jer ^c   Chen, Jyh Yih ^b  

^a NATIONAL SUN YAT SEN UNIVERSITY   (Taiwan)

^b ACADEMIA SINICA   (Taiwan)

^c NATIONAL TAIWAN OCEAN UNIVERSITY   (Taiwan)

Author keywords

Antimicrobial peptide; Cytokine; Epinecidin 1; H. pylori; Treg cells

Indexed keywords

DISEASES; FAILURE ANALYSIS; GASTROENTEROLOGY; GENE EXPRESSION; MICROORGANISMS;

ANTIMICROBIAL PEPTIDE; CYTOKINES; EPINECIDIN-1; H. PYLORI; TREG CELLS;

ANTIBIOTICS;

EPINECIDIN 1; INTERLEUKIN 10; PROTEIN; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; ANTIMICROBIAL CATIONIC PEPTIDE; EPINECIDIN-1, EPINEPHELUS COIOIDES; FISH PROTEIN;

ADULT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIAL CLEARANCE; BACTERIAL LOAD; BACTERICIDAL ACTIVITY; CD4+ FOXP3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; CYTOKINE RESPONSE; DRUG EFFICACY; EYE IRRITATION; FLOW CYTOMETRY; GENE EXPRESSION; HELICOBACTER INFECTION; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LYSIS; MALE; MEMBRANE POTENTIAL; MINIMUM BACTERICIDAL CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; OPTICAL DENSITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RABBIT MODEL; RANDOMIZED CONTROLLED TRIAL; T LYMPHOCYTE; TH17 CELL; ZETA POTENTIAL; ANIMAL; C3H MOUSE; CELL SURVIVAL; CYTOLOGY; DOSE RESPONSE; DRUG EFFECTS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; IMMUNOLOGY; LD50; MEMBRANE FLUIDITY; PATHOLOGY; TREATMENT OUTCOME;

HELICOBACTER PYLORI;

ANIMALS; ANTI-BACTERIAL AGENTS; ANTIMICROBIAL CATIONIC PEPTIDES; CELL SURVIVAL; DOSE-RESPONSE RELATIONSHIP, DRUG; FISH PROTEINS; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; LETHAL DOSE 50; MALE; MEMBRANE FLUIDITY; MICE; MICE, INBRED C3H; TREATMENT OUTCOME;

EID: 84938378640     PISSN: 01429612     EISSN: 18785905     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2015.05.014     Document Type: Article

References (60)

1. Megraud F., Coenen S., Versporten A., Kist M., Lopez-Brea M., Hirschl A.M., et al. Helicobacter pylori resistance to antibiotics in Europe and its relationship to antibiotic consumption. Gut 2013, 62:34-42.
2. Arias C.A., Murray B.E. Antibiotic-resistant bugs in the 21st century-a clinical super-challenge. N. Engl. J. Med. 2009, 360:439-443.
3. Fock K.M., Graham D.Y., Malfertheiner P. Helicobacter pylori research: historical insights and future directions. Nat. Rev. Gastroenterology Hepatology 2013, 10:495-500.
4. Rimbara E., Fischbach L.A., Graham D.Y. Optimal therapy for Helicobacter pylori infections. Nat. Rev. Gastroenterology Hepatology 2011, 8:79-88.
5. Marshall B.J., Warren J.R. Unidentified curved bacilli in the stomach of patients with gastritis and peptic ulceration. Lancet 1984, 1:1311-1315.
6. Fischbach L., Evans E.L. Meta-analysis: the effect of antibiotic resistance status on the efficacy of triple and quadruple first-line therapies for Helicobacter pylori. Alimentary Pharmacol. Ther. 2007, 26:343-357.
7. Megraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004, 53:1374-1384.
8. Chuah S.K., Tsay F.W., Hsu P.I., Wu D.C. A new look at anti-Helicobacter pylori therapy. World J. Gastroenterol. 2011, 17:3971-3975.
9. Borody T.J., Cole P., Noonan S., Morgan A., Lenne J., Hyland L., et al. Recurrence of duodenal ulcer and Campylobacter pylori infection after eradication. Med. J. Aust. 1989, 151:431-435.
10. Lee J.-K., Park S.-C., Hahm K.-S., Park Y. A helix-PXXP-helix peptide with antibacterial activity without cytotoxicity against MDRPA-infected mice. Biomaterials 2014, 35:1025-1039.
11. Wimley W.C., Hristova K. Antimicrobial peptides: successes, challenges and unanswered questions. J. Membr. Biol. 2011, 239:27-34.
12. Brogden K.A. Antimicrobial peptides: pore formers or metabolic inhibitors in bacteria?. Nat. Rev. Microbiol. 2005, 3:238-250.
13. Yount N.Y., Yeaman M.R. Immunocontinuum: perspectives in antimicrobial peptide mechanisms of action and resistance. Protein Peptide Lett. 2005, 12:49-67.
14. Yeaman M.R., Yount N.Y. Mechanisms of antimicrobial peptide action and resistance. Pharmacol. Rev. 2003, 55:27-55.
15. Hancock R.E., Scott M.G. The role of antimicrobial peptides in animal defenses. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:8856-8861.
16. Pan C.Y., Chen J.Y., Cheng Y.S., Chen C.Y., Ni I.H., Sheen J.F., et al. Gene expression and localization of the epinecidin-1 antimicrobial peptide in the grouper (Epinephelus coioides), and its role in protecting fish against pathogenic infection. DNA Cell Biol. 2007, 26:403-413.
17. Lin W.J., Chien Y.L., Pan C.Y., Lin T.L., Chen J.Y., Chiu S.J., et al. Epinecidin-1, an antimicrobial peptide from fish (Epinephelus coioides) which has an antitumor effect like lytic peptides in human fibrosarcoma cells. Peptides 2009, 30:283-290.
18. Lee S.C., Pan C.Y., Chen J.Y. The antimicrobial peptide, epinecidin-1, mediates secretion of cytokines in the immune response to bacterial infection in mice. Peptides 2012, 36:100-108.
19. Huang H.N., Rajanbabu V., Pan C.Y., Chan Y.L., Wu C.J., Chen J.Y. Use of the antimicrobial peptide Epinecidin-1 to protect against MRSA infection in mice with skin injuries. Biomaterials 2013, 34:10319-10327.
20. Pan C.Y., Wu J.L., Hui C.F., Lin C.H., Chen J.Y. Insights into the antibacterial and immunomodulatory functions of the antimicrobial peptide, epinecidin-1, against Vibrio vulnificus infection in zebrafish. Fish Shellfish Immunol. 2011, 31:1019-1025.
21. Pan C.Y., Chen J.Y., Lin T.L., Lin C.H. In vitro activities of three synthetic peptides derived from epinecidin-1 and an anti-lipopolysaccharide factor against Propionibacterium acnes, Candida albicans, and Trichomonas vaginalis. Peptides 2009, 30:1058-1068.
22. Wang Y.D., Kung C.W., Chi S.C., Chen J.Y. Inactivation of nervous necrosis virus infecting grouper (Epinephelus coioides) by epinecidin-1 and hepcidin 1-5 antimicrobial peptides, and downregulation of Mx2 and Mx3 gene expressions. Fish Shellfish Immunol. 2010, 28:113-120.
23. Pan C.Y., Rajanbabu V., Chen J.Y., Her G.M., Nan F.H. Evaluation of the epinecidin-1 peptide as an active ingredient in cleaning solutions against pathogens. Peptides 2010, 31:1449-1458.
24. Pan C.Y., Chen J.C., Sheen J.F., Lin T.L., Chen J.Y. Epinecidin-1 Has immunomodulatory effects, facilitating its therapeutic use in a mouse model of Pseudomonas aeruginosa sepsis. Antimicrob. Agents Chemother. 2014, 58:4264-4274.
25. Klevens R.M., Edwards J.R., Richards C.L., Horan T.C., Gaynes R.P., Pollock D.A., et al. Estimating health care-associated infections and deaths in U.S. hospitals. Public Health Rep. 2002, 2007(122):160-166.
26. Makobongo M.O., Gancz H., Carpenter B.M., McDaniel D.P., Merrell D.S. The oligo-acyl lysyl antimicrobial peptide C(1)(2)K-2beta(1)(2) exhibits a dual mechanism of action and demonstrates strong in vivo efficacy against Helicobacter pylori. Antimicrob. agents Chemother. 2012, 56:378-390.
27. Domingues M.M., Santiago P.S., Castanho M.A.R.B., Santos N.C. What can light scattering spectroscopy do for membrane-active peptide studies?. J. Peptide Sci. 2008, 14:394-400.
28. Papareddy P., Kalle M., Kasetty G., Morgelin M., Rydengard V., Albiger B., et al. C-terminal peptides of tissue factor pathway inhibitor are novel host defense molecules. J. Biol. Chem. 2010, 285:28387-28398.
29. Thamphiwatana S., Gao W., Obonyo M., Zhang L. In vivo treatment of Helicobacter pylori infection with liposomal linolenic acid reduces colonization and ameliorates inflammation. Proc. Natl. Acad. Sci. 2014, 111:17600-17605.
30. Chen X.Y., Liu W.Z., Shi Y., Zhang D.Z., Xiao S.D., Tytgat G.N.J. Helicobacter pylori associated gastric diseases and lymphoid tissue hyperplasia in gastric antral mucosa. J. Clin. Pathology 2002, 55:133-137.
31. Sobala G.M., Crabtree J.E., Dixon M.F., Schorah C.J., Taylor J.D., Rathbone B.J., et al. Acute Helicobacter pylori infection: clinical features, local and systemic immune response, gastric mucosal histology, and gastric juice ascorbic acid concentrations. Gut 1991, 32:1415-1418.
32. Rotimi O., Cairns A., Gray S., Moayyedi P., Dixon M. Histological identification of Helicobacter pylori: comparison of staining methods. J. Clin. Pathology 2000, 53:756-759.
33. King L.E., Fraker P.J. Flow cytometric analysis of the phenotypic distribution of splenic lymphocytes in zinc-deficient adult mice. J. Nutr. 1991, 121:1433-1438.
34. Colovai A.I., Giatzikis C., Ho E.K., Farooqi M., Suciu-Foca N., Cattoretti G., et al. Flow cytometric analysis of normal and reactive spleen. Mod. Pathol. 2004, 17:918-927. an official journal of the United States and Canadian Academy of Pathology, Inc.
35. Obonyo M., Sabet M., Cole S.P., Ebmeyer J., Uematsu S., Akira S., et al. Deficiencies of myeloid differentiation factor 88, Toll-like receptor 2 (TLR2), or TLR4 produce specific defects in macrophage cytokine secretion induced by Helicobacter pylori. Infect. Immun. 2007, 75:2408-2414.
36. Rad R., Brenner L., Krug A., Voland P., Mages J., Lang R., et al. Toll-Like Receptor-Dependent Activation of Antigen-Presenting Cells Affects Adaptive Immunity to Helicobacter pylori. Gastroenterology 2007, 133:150-163.e3.
37. OECD. Test No. 423: Acute Oral toxicity - Acute Toxic Class Method: OECD Publishing.
38. de Almeida Vaucher R., de Campos Velho Gewehr C., Folmer Correa A.P., Sant'Anna V., Ferreira J., Brandelli A. Evaluation of the immunogenicity and in vivo toxicity of the antimicrobial peptide P34. Int. J. Pharm. 2011, 421:94-98.
39. OECD. Test No. 407: Repeated Dose 28-day Oral Toxicity Study in Rodents: OECD Publishing.
40. OECD. Test No. 406: Skin Sensitisation: OECD Publishing.
41. Sekizawa J., Yasuhara K., Suyama Y., Yamanaka S., Tobe M., Nishimura M. A Simple Method For Screening Assessment Of Skin And Eye Irritation. J. Toxicol. Sci. 1994, 19:25-35.
42. OECD. Test No. 405: Acute Eye Irritation/Corrosion: OECD Publishing.
43. Khademi F., Faghri J., Poursina F., Esfahani B.N., Moghim S., Fazeli H., et al. Resistance pattern of Helicobacter pylori strains to clarithromycin, metronidazole, and amoxicillin in Isfahan, Iran. J. Res. Med. Sci. 2013, 18:1056-1060. the official journal of Isfahan University of Medical Sciences.
44. Agudo S., Alarcon T., Cibrelus L., Urruzuno P., Martinez M.J., Lopez-Brea M. [High percentage of clarithromycin and metronidazole resistance in Helicobacter pylori clinical isolates obtained from Spanish children]. Rev. espanola Quimioter. publicacion Of. la Soc. Espanola Quimioter. 2009, 22:88-92.
45. Armstrong J.A., Wee S.H., Goodwin C.S., Wilson D.H. Response of Campylobacter pyloridis to antibiotics, bismuth and an acid-reducing agent in vitro-an ultrastructural study. J. Med. Microbiol. 1987, 24:343-350.
46. Kao J.Y., Zhang M., Miller M.J., Mills J.C., Wang B., Liu M., et al. Helicobacter pylori immune escape is mediated by dendritic cell-induced Treg skewing and Th17 suppression in mice. Gastroenterology 2010, 138:1046-1054.
47. Lin S.B., Fan T.W., Wu J.L., Hui C.F., Chen J.Y. Immune response and inhibition of bacterial growth by electrotransfer of plasmid DNA containing the antimicrobial peptide, epinecidin-1, into zebrafish muscle. Fish Shellfish Immunol. 2009, 26:451-458.
48. Huang T.C., Chen J.Y. Proteomic and functional analysis of zebrafish after administration of antimicrobial peptide epinecidin-1. Fish Shellfish Immunol. 2013, 34:593-598.
49. Stratton C.W., Aldridge K.E., Gelfand M.S. In vitro killing of penicillin-susceptible, -intermediate, and -resistant strains of Streptococcus pneumoniae by cefotaxime, ceftriaxone, and ceftizoxime: a comparison of bactericidal and inhibitory activity with achievable CSF levels. Diagnostic Microbiol. Infect. Dis. 1995, 22:35-42.
50. Yang L., Gordon V.D., Trinkle D.R., Schmidt N.W., Davis M.A., DeVries C., et al. Mechanism of a prototypical synthetic membrane-active antimicrobial: Efficient hole-punching via interaction with negative intrinsic curvature lipids. Proc. Natl. Acad. Sci. U. S. A. 2008, 105:20595-20600.
51. Kronsteiner B., Bassaganya-Riera J., Philipson C., Viladomiu M., Carbo A., Pedragosa M., et al. Helicobacter pylori Infection in a Pig Model Is Dominated by Th1 and Cytotoxic CD8(+) T Cell Responses. Infect. Immun. 2013, 81:3803-3813.
52. Levings M.K., Gregori S., Tresoldi E., Cazzaniga S., Bonini C., Roncarolo M.G. Differentiation of Tr1 cells by immature dendritic cells requires IL-10 but not CD25+CD4+ Tr cells. Blood 2005, 105:1162-1169.
53. Robinson K., Kenefeck R., Pidgeon E.L., Shakib S., Patel S., Polson R.J., et al. Helicobacter pylori-induced peptic ulcer disease is associated with inadequate regulatory T cell responses. Gut 2008, 57:1375-1385.
54. Kabir S. The Role of Interleukin-17 in the Helicobacter pylori induced infection and immunity. Helicobacter 2011, 16:1-8.
55. Maekawa T., Kinoshita Y., Matsushima Y., Okada A., Fukui H., Waki S., et al. Helicobacter pylori induces proinflammatory cytokines and major histocompatibility complex class II antigen in mouse gastric epithelial cells. J. Laboratory Clin. Med. 1997, 130:442-449.
56. Fiorentino M., Ding H., Blanchard T.G., Czinn S.J., Sztein M.B., Fasano A. Helicobacter pylori-induced disruption of monolayer permeability and proinflammatory cytokine secretion in polarized human gastric epithelial cells. Infect. Immun. 2013, 81:876-883.
57. Weigert N, Schaffer K, Schusdziarra V, Classen M, Schepp W. Gastrin secretion from primary cultures of rabbit antral G cells: Stimulation by inflammatory cytokines. Gastroenterology.110:147-154.
58. Noach L.A., Bosma N.B., Jansen J., Hoek F.J., van Deventer S.J., Tytgat G.N. Mucosal tumor necrosis factor-alpha, interleukin-1 beta, and interleukin-8 production in patients with Helicobacter pylori infection. Scand. J. gastroenterology 1994, 29:425-429.
59. Eisenstein E.M., Williams C.B. The Treg/Th17 Cell Balance: a new paradigm for autoimmunity. Pediatr. Res. 2009, 65:26R-31R.
60. Huang H.N., Rajanbabu V., Pan C.Y., Chan Y.L., Wu C.J., Chen J.Y. Use of the antimicrobial peptide Epinecidin-1 to protect against MRSA infection in mice with skin injuries. Biomaterials 2013, 34:10319-10327.